Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Rxo (RXO) Depreciation & Amortization (IS) (2021 - 2025)

Historic Depreciation & Amortization (IS) for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $28.0 million.

  • Rxo's Depreciation & Amortization (IS) fell 1515.15% to $28.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $116.0 million, marking a year-over-year increase of 3333.33%. This contributed to the annual value of $116.0 million for FY2025, which is 3333.33% up from last year.
  • According to the latest figures from Q4 2025, Rxo's Depreciation & Amortization (IS) is $28.0 million, which was down 1515.15% from $26.0 million recorded in Q3 2025.
  • In the past 5 years, Rxo's Depreciation & Amortization (IS) registered a high of $33.0 million during Q4 2024, and its lowest value of $15.0 million during Q4 2023.
  • For the 5-year period, Rxo's Depreciation & Amortization (IS) averaged around $22.1 million, with its median value being $21.0 million (2022).
  • Per our database at Business Quant, Rxo's Depreciation & Amortization (IS) crashed by 3043.48% in 2023 and then surged by 12000.0% in 2024.
  • Rxo's Depreciation & Amortization (IS) (Quarter) stood at $19.0 million in 2021, then rose by 10.53% to $21.0 million in 2022, then fell by 28.57% to $15.0 million in 2023, then surged by 120.0% to $33.0 million in 2024, then decreased by 15.15% to $28.0 million in 2025.
  • Its last three reported values are $28.0 million in Q4 2025, $26.0 million for Q3 2025, and $30.0 million during Q2 2025.